[go: up one dir, main page]

MX2009013728A - Derivados de bicicloanilina. - Google Patents

Derivados de bicicloanilina.

Info

Publication number
MX2009013728A
MX2009013728A MX2009013728A MX2009013728A MX2009013728A MX 2009013728 A MX2009013728 A MX 2009013728A MX 2009013728 A MX2009013728 A MX 2009013728A MX 2009013728 A MX2009013728 A MX 2009013728A MX 2009013728 A MX2009013728 A MX 2009013728A
Authority
MX
Mexico
Prior art keywords
sup
substituted
aliphatic ring
ring
group
Prior art date
Application number
MX2009013728A
Other languages
English (en)
Inventor
Makoto Bamba
Keiji Takahashi
Kenji Niiyama
Toshihiro Sakamoto
Satoshi Sunami
Fuyuki Yamamoto
Hidetomo Furuyama
Takashi Yoshizumi
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of MX2009013728A publication Critical patent/MX2009013728A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a un compuesto de fórmula general (I): (ver fórmula) en donde A1 y A2 significan, cada uno, un átomo de nitrógeno o un grupo metino sustituido opcionalmente; el anillo B significa un anillo alifático de 5 a 7 miembros, un anillo espiro o bicíclico formado del anillo alifático y cualquier otro anillo alifático de 3 a 7 miembros; R1 significa un átomo de hidrógeno, o un grupo alquilo de C1-C6 sustituido opcionalmente, o un grupo arilo, aralquilo o heteroarilo sustituido opcionalmente; R2 significa un grupo arilo, aralquilo o heteroarilo sustituido opcionalmente; y X significa un grupo =NH u=O, etc.; basándose en su excelente efecto inhibidor de la cinasa Wee1, el compuesto de la invención tiene un efecto inhibidor del crecimiento celular y tiene un efecto aditivo/sinérgico con cualquier otro agente anticanceroso, y por lo tanto es útil en el campo de la medicina.
MX2009013728A 2007-06-15 2008-06-12 Derivados de bicicloanilina. MX2009013728A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007159217 2007-06-15
US96591807P 2007-08-23 2007-08-23
PCT/JP2008/061182 WO2008153207A1 (ja) 2007-06-15 2008-06-12 ビシクロアニリン誘導体

Publications (1)

Publication Number Publication Date
MX2009013728A true MX2009013728A (es) 2010-01-25

Family

ID=40129803

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013728A MX2009013728A (es) 2007-06-15 2008-06-12 Derivados de bicicloanilina.

Country Status (22)

Country Link
US (1) US8436004B2 (es)
EP (1) EP2168966B1 (es)
JP (1) JP5129812B2 (es)
KR (1) KR20100024932A (es)
CN (1) CN101784551A (es)
AU (1) AU2008262837B2 (es)
CA (1) CA2689429C (es)
CY (1) CY1118448T1 (es)
DK (1) DK2168966T3 (es)
ES (1) ES2608940T3 (es)
HR (1) HRP20161536T1 (es)
HU (1) HUE032403T2 (es)
IL (1) IL202262A0 (es)
LT (1) LT2168966T (es)
MX (1) MX2009013728A (es)
NZ (1) NZ581936A (es)
PL (1) PL2168966T3 (es)
PT (1) PT2168966T (es)
RU (1) RU2010101052A (es)
SI (1) SI2168966T1 (es)
WO (1) WO2008153207A1 (es)
ZA (1) ZA200908298B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090253693A1 (en) * 2008-04-07 2009-10-08 Dmitry Koltun 2H-BENZO[b][1,4]OXAZIN-3(4H)-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
WO2009151997A1 (en) * 2008-06-12 2009-12-17 Merck & Co., Inc. Process for producing bicycloaniline derivatives
WO2010067888A1 (en) * 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivatives
JP2012511502A (ja) 2008-12-12 2012-05-24 Ｍｓｄ株式会社 ジヒドロピリミドピリミジン誘導体
WO2010098367A1 (en) * 2009-02-25 2010-09-02 Banyu Pharmaceutical Co.,Ltd. Pyrimidopyrimidoindazole derivative
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US8796289B2 (en) 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
US9345705B2 (en) 2011-09-15 2016-05-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
CN103113311A (zh) * 2012-07-19 2013-05-22 南京邮电大学 一类2-芳基喹唑啉或2-杂环芳基喹唑啉衍生物及其制备方法
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
KR102350704B1 (ko) 2013-03-15 2022-01-13 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
CN111793068A (zh) 2013-03-15 2020-10-20 西建卡尔有限责任公司 杂芳基化合物和其用途
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
CN104725333A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种新的氮杂环庚烷衍生物的制备方法
JP2017517520A (ja) * 2014-05-29 2017-06-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｗｅｅ１阻害剤を用いた癌を処置する方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2017031116A1 (en) * 2015-08-18 2017-02-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of ku70/80 and uses thereof
EP3380194B1 (en) * 2015-11-24 2023-11-01 Indiana University Research & Technology Corporation Composition for blocking angiogenesis
KR102220971B1 (ko) 2016-12-20 2021-02-25 아스트라제네카 아베 아미노-트리아졸로피리딘 화합물 및 암 치료에서의 이의 용도
KR20190130621A (ko) 2017-03-31 2019-11-22 시애틀 지네틱스, 인크. Chk1 저해제와 wee1 저해제의 조합물
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3694861A4 (en) 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2019074981A1 (en) * 2017-10-09 2019-04-18 GiraFpharma LLC HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2019096322A1 (zh) * 2017-11-20 2019-05-23 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
EP3952879A4 (en) * 2019-04-09 2023-01-04 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
US20220168313A1 (en) * 2019-04-09 2022-06-02 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
BR112021019703A2 (pt) 2019-04-09 2021-12-14 Nuvation Bio Inc Compostos heterocíclicos e usos dos mesmos
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN112442049A (zh) * 2019-09-03 2021-03-05 微境生物医药科技(上海)有限公司 作为Wee1抑制剂的嘧啶衍生物
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076602A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN114599399A (zh) 2019-10-25 2022-06-07 阿斯利康(瑞典)有限公司 治疗癌症的方法
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
CN115151539A (zh) 2019-12-04 2022-10-04 因赛特公司 Fgfr抑制剂的衍生物
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN116888107A (zh) * 2021-02-19 2023-10-13 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的稠环化合物
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
US20240252655A1 (en) 2021-04-29 2024-08-01 Novartis Ag Deubiquitinase-targeting chimeras and related methods
BR112023022236A2 (pt) * 2021-04-30 2024-02-06 Wigen Biomedicine Tech Shanghai Co Ltd Composto de fórmula geral (1) ou seu isômero, forma cristalina, sal farmaceuticamente aceitável, hidrato ou solvato; composição farmacêutica; e; uso do composto ou seu isômero, forma cristalina, sal farmaceuticamente aceitável, hidrato ou solvato
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
EP4489756A1 (en) 2022-03-07 2025-01-15 Debiopharm International SA Methods of treating small cell lung cancer
TW202519221A (zh) 2023-09-14 2025-05-16 瑞士商德彪製藥國際公司 Ｗｅｅ１抑制劑及ｐｋｍｙｔ１抑制劑之組合
TW202541810A (zh) 2023-12-22 2025-11-01 瑞士商德彪製藥國際公司 治療實體腫瘤之方法
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010043829A (ko) * 1998-05-26 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 비시클릭 피리미딘 및 비시클릭3,4-디히드로피리미딘
BR0109056A (pt) * 2000-03-06 2003-06-03 Warner Lambert Co Inibidores da cinase de tirosina de 5-alquilpirido[2,3-d]pirimidinas
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
PA8577501A1 (es) * 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
TW200413381A (en) 2002-11-04 2004-08-01 Hoffmann La Roche Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
WO2004045283A2 (de) * 2002-11-15 2004-06-03 Basf Aktiengesellschaft Fungizide mischungen zur bekämpfung von reispathogenen
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
FR2873118B1 (fr) * 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
EP1794160A1 (en) * 2004-09-21 2007-06-13 F.Hoffmann-La Roche Ag 6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as proteine kinase inhibitors
AU2006264212B2 (en) 2005-06-29 2010-10-28 Compumedics Limited Sensor assembly with conductive bridge
RU2475488C2 (ru) * 2006-02-14 2013-02-20 Вертекс Фармасьютикалз Инкорпорейтед Дигидродиазепины, которые можно использовать в качестве ингибиторов протеинкиназ

Also Published As

Publication number Publication date
KR20100024932A (ko) 2010-03-08
AU2008262837A1 (en) 2008-12-18
CN101784551A (zh) 2010-07-21
NZ581936A (en) 2011-08-26
SI2168966T1 (sl) 2017-03-31
HUE032403T2 (en) 2017-09-28
PL2168966T3 (pl) 2017-06-30
CA2689429A1 (en) 2008-12-18
EP2168966A1 (en) 2010-03-31
JP5129812B2 (ja) 2013-01-30
IL202262A0 (en) 2010-06-16
JPWO2008153207A1 (ja) 2010-08-26
EP2168966A4 (en) 2011-02-16
ZA200908298B (en) 2010-08-25
HRP20161536T1 (hr) 2016-12-30
WO2008153207A1 (ja) 2008-12-18
LT2168966T (lt) 2017-01-10
EP2168966B1 (en) 2016-09-28
PT2168966T (pt) 2017-01-02
CA2689429C (en) 2012-08-21
RU2010101052A (ru) 2011-07-20
US20110135601A1 (en) 2011-06-09
DK2168966T3 (en) 2017-01-23
AU2008262837B2 (en) 2013-05-23
ES2608940T3 (es) 2017-04-17
US8436004B2 (en) 2013-05-07
CY1118448T1 (el) 2017-06-28

Similar Documents

Publication Publication Date Title
MX2009013728A (es) Derivados de bicicloanilina.
WO2009054332A1 (ja) ピリドン置換ジヒドロピラゾロピリミジノン誘導体
PH12012501711A1 (en) [5,6] heterocyclic compound
MY152972A (en) Azabicyclo compound and salt thereof
MY160443A (en) Nitrogen-containing heterocyclic compound and agricultural fungicide
EP1604665A4 (en) C-KIT KINASE HEMMER
MY158240A (en) Nitrogenated heterocyclic compound and agricultural or horticultural fungicide
WO2005097129A3 (en) 6-azaindole compound
MX2013002558A (es) Derivado de imidazol de heteroanillo fusionado que tiene efecto de activacion de proteina cinasa activada por monofosfato de adenosina (amk).
MX2009010024A (es) Nuevo compuesto de adenina.
MX2010003394A (es) Derivado de gamma-aminoacido biciclico.
MX344276B (es) Compuesto de piperidina novedoso o sal del mismo.
MY154772A (en) Harmful arthropod control composition, and fused heterocyclic compound
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
TNSN07397A1 (en) Acetylene derivatives
MX2009012885A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco
MX2010013275A (es) Compuesto novedoso de uracilo o su sal que tiene actividad inhibidora de desoxiuridin trifosfatasa de humano.
MX2009010823A (es) Compuesto de hidrazida y agente controlador de artropodos dañinos que contiene el mismo.
WO2009041447A1 (ja) ５員複素環化合物
MY182716A (en) Method for controlling arthropod pest
TW200612920A (en) Novel imidazolidine derivatives
MY144633A (en) New tricyclic derivatives, method of preparing same and pharmaceutical compositions containing them
MX2013007938A (es) Compuesto biciclico novedoso o sal del mismo.
WO2008139845A1 (ja) 新規アミド誘導体
WO2008105398A1 (ja) Ｃｂｐ化合物

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: MSD K.K.

FA Abandonment or withdrawal